Followers | 13 |
Posts | 1365 |
Boards Moderated | 0 |
Alias Born | 05/05/2006 |
Thursday, December 02, 2010 8:53:56 PM
Internal Update
Wednesday, December 02, 2010
NanoLogix is extremely pleased to announce that Ahmer Kodvawala has been appointed Director of its Research and Product Development Laboratory in Cincinnati. Ahmer Kodvawala earned an MBA degree from the University of Cincinnati that included advanced work in Corporate Strategy, Project Management, and New Product Development. He also received a Master of Science degree in Medical Genetics at the University of Newcastle in the United Kingdom. While he was working in the NanoLogix lab since June 2010, it became clear that Ahmer brings a unique blend of experience, business expertise and research skills of a kind that were not available to the company with the laboratory staff as constituted. Management made the decision that the abilities offered by its new Director of Research and Development are vital to the company’s growth as NanoLogix moves into an exciting stage of product refinement and marketing.
Reasons for this strategic decision include the fact that Ahmer Kodvawala has proved to be a meticulous scientist with experience in molecular biology and diagnostics in addition to his strong management and marketing skills gained through Cincinnati’s MBA program and his entrepreneurial experience in a start-up bio-consulting firm. He possesses the ability to facilitate effective team work with colleagues and has demonstrated multi-tasking skills in complex cross cultural environments. During his career he has coordinated research projects on lipid metabolism and pathophysiology of atherosclerosis, generated and characterized a cholesterol esterase lipase transgenic mouse which significantly advanced technical understanding of the enzyme’s role in atherosclerosis, and led a National Institute of Health (NIH) RO1 grant to study lipoprotein complications of HIV infection and HIV therapy. He is the author or coauthor of multiple scientific papers.
________________________________________
Contact:
NanoLogix, Inc.
Investor Relations
Carol Surrena
Telephone: 330-534-0800
E-mail: carol@nanologix.com
Parents
Transforming Alzheimer's Treatment: Innovative Combinations to Boost Cognition • PFE • Oct 2, 2024 9:00 AM
Unitronix Corp Unveils Cryptocurrency Investment Portfolio Strategy • UTRX • Oct 2, 2024 8:40 AM
Integrated Ventures, Inc Reports Total 2024 Revenues Of $5,863,935 vs $3,862,849 for 2023. • INTV • Oct 1, 2024 9:00 AM
Nightfood Signs Letter of Intent to Acquire Los Angeles Cooking School, Integrating Automation and Robotics with World-Class Culinary Training • NGTF • Oct 1, 2024 8:30 AM
ZenaTech, Inc. (NASDAQ: ZENA) To Commence Trading Today • COOP • Oct 1, 2024 7:00 AM
Element79 Gold Corp secures loi for launching tailings reprocessing business in Arequipa, Peru • ELMGF • Oct 1, 2024 6:38 AM